Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amitesh Roy

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Journal for Immunotherapy of Cancer|November 21, 2020
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanomaVictoria Atkinson, Adnan Khattak, Andrew Haydon, et al.
Clinical Colorectal Cancer|May 13, 2026
Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert PerspectiveMatthew Burge, Jeanne Tie, Tharani Krishnan, et al.
Expert Review of Anticancer Therapy|June 6, 2025
The current landscape of neoadjuvant therapy for resectable colon cancerMei Chan, Tharani Krishnan, Amanda Townsend, et al.
Molecular Oncology|January 9, 2022
Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1Erin L Symonds, Susanne K Pedersen, Bernita Yeo, et al.
Expert Review of Anticancer Therapy|December 24, 2024
Role of locoregional therapy including liver transplantation in liver-only metastatic colorectal cancer: a review paperLaura Depauw, Amanda Townsend, Christos Karapetis, et al.
Annals of Surgical Oncology|June 3, 2016
Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal RegistryDainik Patel, Amanda R Townsend, Christos Karapetis, et al.
Biomarker Insights|March 1, 2024
Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal CancerHiba Al Naji, Jean M Winter, Susanne K Pedersen, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2018
Observation of "complete clinical response" in rectal cancer after neoadjuvant chemoradiation: The Flinders experienceLuigi A Sposato, Yick Lam, Chris Karapetis, et al.
ANZ Journal of Surgery|October 7, 2021
Patterns of care and outcomes for gastric and gastro-oesophageal junction cancer in an Australian populationM Nazim Abbas, Tim Bright, Timothy Price, et al.
Journal of Cancer Research and Clinical Oncology|July 12, 2018
Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survivalDavid H Murray, Erin L Symonds, Graeme P Young, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|November 21, 2020
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanomaVictoria Atkinson, Adnan Khattak, Andrew Haydon, et al.
Clinical Colorectal Cancer|May 13, 2026
Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert PerspectiveMatthew Burge, Jeanne Tie, Tharani Krishnan, et al.
Expert Review of Anticancer Therapy|June 6, 2025
The current landscape of neoadjuvant therapy for resectable colon cancerMei Chan, Tharani Krishnan, Amanda Townsend, et al.
Molecular Oncology|January 9, 2022
Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1Erin L Symonds, Susanne K Pedersen, Bernita Yeo, et al.
Expert Review of Anticancer Therapy|December 24, 2024
Role of locoregional therapy including liver transplantation in liver-only metastatic colorectal cancer: a review paperLaura Depauw, Amanda Townsend, Christos Karapetis, et al.
Annals of Surgical Oncology|June 3, 2016
Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal RegistryDainik Patel, Amanda R Townsend, Christos Karapetis, et al.
Biomarker Insights|March 1, 2024
Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal CancerHiba Al Naji, Jean M Winter, Susanne K Pedersen, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2018
Observation of "complete clinical response" in rectal cancer after neoadjuvant chemoradiation: The Flinders experienceLuigi A Sposato, Yick Lam, Chris Karapetis, et al.
ANZ Journal of Surgery|October 7, 2021
Patterns of care and outcomes for gastric and gastro-oesophageal junction cancer in an Australian populationM Nazim Abbas, Tim Bright, Timothy Price, et al.
Journal of Cancer Research and Clinical Oncology|July 12, 2018
Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survivalDavid H Murray, Erin L Symonds, Graeme P Young, et al.
Pageof 5